$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000032001716000162 Filed on November 07, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$0.00	$9.317M	$7.560K
YoY Change	-100.0%	58.23%	43.29%
Cost Of Revenue		$8.611M	$6.230M
YoY Change		79.08%	47.98%
Gross Profit		$706.3K	$1.330M
YoY Change		-34.59%	24.3%
Gross Profit Margin		7.58%	17592.59%
Selling, General & Admin	$2.290M	$2.769M	$4.990M
YoY Change	-54.11%	-46.2%	-22.64%
% of Gross Profit		392.05%	375.19%
Research & Development	$3.200M	$2.959M	$3.150M
YoY Change	1.59%	-53.15%	-68.93%
% of Gross Profit		418.91%	236.84%
Depreciation & Amortization	$100.0K	$100.0K	$800.0K
YoY Change	-87.5%	-84.37%	31.15%
% of Gross Profit		14.16%	60.15%
Operating Expenses	$5.490M	$5.728M	$8.170M
YoY Change	-32.8%	-64.8%	-50.84%
Operating Profit		-$5.728M	-$6.840M
YoY Change		-44.84%	-56.01%
Interest Expense	-$180.0K	$368.4K	-$480.0K
YoY Change	-62.5%	-33.39%	29.73%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$363.2K	$13.32M
YoY Change	-100.0%	-62.29%	233.83%
Pretax Income	-$5.670M	-$6.091M	-$33.23K
YoY Change	16963.92%	-46.32%	184.22%
Income Tax	$0.00	$0.00	-$13.63M
% Of Pretax Income
Net Earnings	-$5.960M	-$7.288M	-$33.20K
YoY Change	17853.43%	63961.23%	185.89%
Net Earnings / Revenue		-78.21%	-439.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$727.7K	-$1.089M	-$5.887M
COMMON SHARES
Basic Shares Outstanding	8.169M shares	5.914M shares	55.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.077M	$18.60M	$18.66M
YoY Change	-62.07%	-36.72%	-28.93%
Cash & Equivalents	$7.077M	$18.61M	$18.66M
Short-Term Investments	$0.00		$0.00
Other Short-Term Assets	$17.40M	$7.100M	$6.400M
YoY Change	171.88%	5.97%	-7.25%
Inventory
Prepaid Expenses
Receivables	$138.8K	$4.275M	$2.566M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.65M	$29.96M	$29.27M
YoY Change	-15.79%	-22.13%	-19.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$705.4K	$17.12M	$17.06M
YoY Change	-95.87%	0.17%	6.92%
Goodwill	$7.013M	$7.013M	$7.000M
YoY Change	0.19%	-72.18%	-72.23%
Intangibles	$2.308M	$2.450M	$2.878M
YoY Change	-19.81%	-93.5%	-93.95%
Long-Term Investments
YoY Change
Other Assets	$1.582M	$726.8K	$976.8K
YoY Change	61.98%	-39.92%	-22.69%
Total Long-Term Assets	$28.87M	$27.31M	$27.93M
YoY Change	3.34%	-66.37%	-68.96%
TOTAL ASSETS
Total Short-Term Assets	$24.65M	$29.96M	$29.27M
Total Long-Term Assets	$28.87M	$27.31M	$27.93M
Total Assets	$53.51M	$57.28M	$57.21M
YoY Change	-6.45%	-52.15%	-54.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.227M	$3.246M	$4.107M
YoY Change	-45.79%	31.57%	-27.45%
Accrued Expenses	$2.659M	$6.373M	$6.198M
YoY Change	-57.1%	-20.45%	43.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.126M	$2.320M	$4.171M
YoY Change	-25.05%	-15.69%	275.94%
Total Short-Term Liabilities	$21.18M	$18.55M	$21.02M
YoY Change	0.8%	-6.01%	29.37%
LONG-TERM LIABILITIES
Long-Term Debt	$2.525M	$3.332M	$10.83M
YoY Change	-76.68%	-72.8%	-22.04%
Other Long-Term Liabilities	$389.9K	$370.1K	$562.0K
YoY Change	-30.63%	-89.3%	-30.15%
Total Long-Term Liabilities	$28.37M	$3.702M	$33.92M
YoY Change	-16.38%	-76.43%	-50.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.18M	$18.55M	$21.02M
Total Long-Term Liabilities	$28.37M	$3.702M	$33.92M
Total Liabilities	$30.05M	$27.89M	$33.92M
YoY Change	-11.42%	-56.9%	-50.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$404.8M	-$398.8M	-$372.1M
YoY Change	8.78%	17.67%	27.77%
Common Stock	$8.206K	$8.182K	$5.673K
YoY Change	44.65%	-85.26%	-84.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$707.6K	$707.6K	$707.6K
YoY Change	0.0%	0.27%	0.27%
Treasury Stock Shares	11.08K shares	11.00K shares	11.00K shares
Shareholders Equity	$4.884M	$10.75M	$23.71M
YoY Change
Total Liabilities & Shareholders Equity	$53.51M	$57.28M	$57.21M
YoY Change	-6.45%	-52.15%	-54.7%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	-$5.960M	-$7.288M	-$33.20K
YoY Change	17853.43%	63961.23%	185.89%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$800.0K
YoY Change	-87.5%	-84.37%	31.15%
Cash From Operating Activities	-$3.380M	-$5.710M	-$8.730M
YoY Change	-61.28%	-34.37%	-19.98%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$0.00	-$620.0K
YoY Change	-95.16%	-100.0%	-15.07%
Acquisitions
YoY Change
Other Investing Activities	-$500.0K	-$610.0K	$5.330M
YoY Change	-109.38%	-74.48%	-182.51%
Cash From Investing Activities	-$530.0K	-$620.0K	$4.720M
YoY Change	-111.23%	-80.32%	-165.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	7.240M	280.0K
YoY Change	-100.0%	-2435.48%	-94.53%
NET CHANGE
Cash From Operating Activities	-3.380M	-5.710M	-8.730M
Cash From Investing Activities	-530.0K	-620.0K	4.720M
Cash From Financing Activities	0.000	7.240M	280.0K
Net Change In Cash	-3.910M	910.0K	-3.730M
YoY Change	4.83%	-107.48%	-71.26%
FREE CASH FLOW
Cash From Operating Activities	-$3.380M	-$5.710M	-$8.730M
Capital Expenditures	-$30.00K	$0.00	-$620.0K
Free Cash Flow	-$3.350M	-$5.710M	-$8.110M
YoY Change	-58.69%	-27.99%	-20.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	clbs	Warrants Expired WarrantsExpired	0	shares
CY2016Q3	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
	clbs	Warrants Granted WarrantsGranted	141845	shares
CY2015	clbs	Revene Recognition Period For Cryoperservation Process ReveneRecognitionPeriodForCryoperservationProcess	PT24H
	clbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	29.16
CY2016Q2	clbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	362399	shares
CY2016Q1	clbs	Subsidiary Ownership Interest By Parent SubsidiaryOwnershipInterestByParent	0.801
	clbs	Warrants Canceled WarrantsCanceled	100850	shares
	clbs	Warrants Exercised WarrantsExercised	0	shares
CY2015Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2016Q2	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2016Q2	clbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	USD
CY2016Q2	clbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	USD
	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2015Q2	clbs	Clinical Services Reimbursement ClinicalServicesReimbursement	900000	USD
	clbs	Clinical Services Reimbursement ClinicalServicesReimbursement	2300000	USD
CY2016Q2	clbs	Clinical Services Reimbursement ClinicalServicesReimbursement	1600000	USD
	clbs	Clinical Services Reimbursement ClinicalServicesReimbursement	5000000	USD
CY2015Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	321404	shares
CY2016Q2	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	362399	shares
CY2016Q1	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	141844	shares
CY2016Q1	clbs	Debt Instrument Maximum Payment To Lender Based On Receipt Of Proceeds From Eligible Events DebtInstrumentMaximumPaymentToLenderBasedOnReceiptOfProceedsFromEligibleEvents	3000000	USD
	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	3147091	USD
	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-879228	USD
CY2015	clbs	Interim Efficacy Analysis Followup Milestone Period InterimEfficacyAnalysisFollowupMilestonePeriod	P6Y
CY2015	clbs	Interim Efficacy Analysis Percentage Threshold InterimEfficacyAnalysisPercentageThreshold	0.50
CY2015Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
	clbs	Weighted Average Estimated Fair Value Of Restricted Stock WeightedAverageEstimatedFairValueOfRestrictedStock	6.05
	clbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	145.10
CY2016Q2	clbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	85.40
	clbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0.00
	clbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	0.00
	clbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	10.00
CY2015Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	137.20
CY2016Q2	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	85.40
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	clbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P1Y0M29D
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	396547401	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	410276001	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2016Q2	clbs	Weighted Average Exercise Price Warrantsvestedexpectedtovest WeightedAverageExercisePriceWarrantsvestedexpectedtovest	85.40
CY2015	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P1Y3M4D
	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P1Y0M29D
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8169407	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Caladrius Biosciences, Inc.
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4107388	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3245779	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2566101	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4274800	USD
	us-gaap	Accretion Expense AccretionExpense	77577	USD
	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6198488	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6372789	USD
CY2015Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	6198400	USD
CY2016Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	6372800	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	480700	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	376700	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	486	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	436500	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8568500	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	335500	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2275600	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	572500	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151300	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	453900	USD
CY2016Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	142500	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	427500	USD
CY2015Q4	us-gaap	Assets Assets	57205295	USD
CY2016Q3	us-gaap	Assets Assets	57278938	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	29272432	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	29964763	USD
CY2016Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	4391900	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	6874800	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	4391900	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	500	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6081900	USD
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8181921	shares
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis	4391400	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	4391400	USD
CY2016Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4380000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2015Q4	us-gaap	Cash Cash	6875600	USD
CY2016Q3	us-gaap	Cash Cash	4391400	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19174061	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24042699	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20318411	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18606743	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4868638	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1711668	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.00
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5673302	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8181921	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5673302	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	5673	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	8182	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11376937	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47689557	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6882533	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26698652	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-16908	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-93257	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-405072	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-522005	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11393845	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-47782814	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7287605	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-27220657	USD
CY2015Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	0.01	shares
CY2016Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	0.01	shares
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	4808679	USD
	us-gaap	Cost Of Revenue CostOfRevenue	13976087	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	8611208	USD
	us-gaap	Cost Of Revenue CostOfRevenue	21891010	USD
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	2911743	USD
CY2016Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	4315977	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5345225	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5869586	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	932662	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1079948	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	800	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1893028	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2093153	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.40
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.09
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.45
CY2015Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2771200	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	4093000	USD
CY2016Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.199
CY2015Q4	us-gaap	Fair Value Estimate Not Practicable Investments FairValueEstimateNotPracticableInvestments	6875600	USD
CY2016Q3	us-gaap	Fair Value Estimate Not Practicable Investments FairValueEstimateNotPracticableInvestments	4391400	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2822100	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3249600	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	27900	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	142500	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	570000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	570000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	570000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	570000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5700000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5700000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2877900	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2450400	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2450400	USD
CY2015Q4	us-gaap	Goodwill Goodwill	7013315	USD
CY2016Q3	us-gaap	Goodwill Goodwill	7013315	USD
CY2016Q2	us-gaap	Goodwill Gross GoodwillGross	7000000	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18200000	USD
CY2015Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	9400000	USD
CY2016Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	591307	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-16907	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-93257	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-405072	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-522005	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1708699	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11346224	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51392460	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7240651	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27072885	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46633	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3610097	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46954	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	147286	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-815231	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	3610097	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-147286	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1163954	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4854312	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	781629	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1404234	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-53743	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-249493	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-908011	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-708935	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2877880	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2450380	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	552983	USD
	us-gaap	Interest Expense InterestExpense	1651222	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	384915	USD
	us-gaap	Interest Expense InterestExpense	1671457	USD
CY2015Q2	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	300000	USD
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	1000000	USD
CY2016Q2	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	200000	USD
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	700000	USD
	us-gaap	Interest Paid InterestPaid	1122479	USD
	us-gaap	Interest Paid InterestPaid	1679880	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	8568605	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2275616	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1200000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1500000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	33921471	USD
CY2016Q3	us-gaap	Liabilities Liabilities	27889443	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57205295	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57278938	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21015223	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18553232	USD
CY2016Q2	us-gaap	Long Term Debt LongTermDebt	6700000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4171456	USD
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2319844	USD
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3100000	USD
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3500000	USD
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	100000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10828544	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2573784	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2315753	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-486	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-988	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-451	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-486	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-988	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-451	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-486	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	562001	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	370081	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0	USD
CY2016Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	4329950	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-410233	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4398585	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5117	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17662	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	100000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-921156	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2315753	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1653795	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30530623	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3331510	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	583041	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	224722	USD
CY2015Q4	us-gaap	Marketable Securities Restricted Current MarketableSecuritiesRestrictedCurrent	6875600	USD
CY2016Q3	us-gaap	Marketable Securities Restricted Current MarketableSecuritiesRestrictedCurrent	4391400	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	-429709	USD
CY2016Q3	us-gaap	Minority Interest MinorityInterest	-756495	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36320417	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20896315	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20292230	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11375950	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47689106	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6882533	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26698166	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-963216	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2747363	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-379798	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	1800000	USD
CY2016Q2	us-gaap	Notes Payable NotesPayable	1000000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1192666	USD
CY2016Q3	us-gaap	Notes Payable Current NotesPayableCurrent	745234	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	16271458	USD
	us-gaap	Operating Expenses OperatingExpenses	69067514	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	16178326	USD
	us-gaap	Operating Expenses OperatingExpenses	50526481	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10383008	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54139823	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6860853	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25419090	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5398600	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	960200	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	994900	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1046700	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1876500	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	520300	USD
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	221500000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2946500	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1903100	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	976768	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	726787	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-451	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3476177	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2767243	USD
	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	19400000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	36136839	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11650712	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1087361	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	368615	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7734528	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	-11392857	USD
	us-gaap	Profit Loss ProfitLoss	-47782363	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	-7287605	USD
	us-gaap	Profit Loss ProfitLoss	-27220171	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17064900	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17123693	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3774	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	USD
CY2016Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	19400000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	9348646	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	903783	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1174366	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6315613	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20719989	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2630632	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12534775	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-372132490	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398830656	USD
CY2015Q3	us-gaap	Revenues Revenues	5888450	USD
	us-gaap	Revenues Revenues	14927691	USD
CY2016Q3	us-gaap	Revenues Revenues	9317473	USD
	us-gaap	Revenues Revenues	25107391	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5147166	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24971438	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4936486	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6001572	shares
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16100696	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	362650	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	200	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2016Q1	us-gaap	Share Price SharePrice	7.05
CY2016Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.72
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	81184	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	107719	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36136839	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11650712	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2367500	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	651700	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8568605	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2275616	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	23713533	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	10745990	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58073789	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54996419	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5523912	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4586757	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6323427	shares
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23283824	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9989495	USD
CY2016Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	10999	shares
CY2016Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	10999	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	707637	USD
CY2016Q3	us-gaap	Treasury Stock Value TreasuryStockValue	707637	USD

Files In Submission

Name	View Source	Status
0000320017-16-000162-index-headers.html	Edgar Link	pending
0000320017-16-000162-index.html	Edgar Link	pending
0000320017-16-000162.txt	Edgar Link	pending
0000320017-16-000162-xbrl.zip	Edgar Link	pending
clbs-10qx20160930.htm	Edgar Link	pending
clbs-20160930.xml	Edgar Link	completed
clbs-20160930.xsd	Edgar Link	pending
clbs-20160930_cal.xml	Edgar Link	unprocessable
clbs-20160930_def.xml	Edgar Link	unprocessable
clbs-20160930_lab.xml	Edgar Link	unprocessable
clbs-20160930_pre.xml	Edgar Link	unprocessable
clbs-ex311_20160930xq3.htm	Edgar Link	pending
clbs-ex312_20160930xq3.htm	Edgar Link	pending
clbs-ex321_20160930xq3.htm	Edgar Link	pending
clbs-ex322_20160930xq3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2016 Q4 Form 10-Q Financial Statement

#000032001716000162 Filed on November 07, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2016 Q4 Form 10-Q Financial Statement

#000032001716000162 Filed on November 07, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta